AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...
AbbVie (NYSE:ABBV) just scored a big win for its next-generation arthritis drug. The company said Monday that Rinvoq ...
MedPage Today on MSN
Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis
ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...
I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
That’s why we need Senate Bill 41, authored by Sen. Scott Wiener, D-San Francisco, which will require a more fair and ...
Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...
The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, ...
Korean biosimilar giant Celltrion announced Monday it has received additional approval from the US Food and Drug ...
With $70 million and a phase 2 ready asset in hand, British biotech Elevara Medicines has emerged to try to revolutionize the ...
The stock's forward yield of 2.8% is higher than the S&P 500 's average of 1.2%, and its cash payout ratio of 61.8% is ...
YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...
Waltz Connect is built on AI-enabled prescription routing technology as well as a specialty marketplace that encourages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback